The TNFR1 Antagonist Atrosimab Is Therapeutic in Mouse Models of Acute and Chronic Inflammation

Therapeutics that block tumor necrosis factor (TNF), and thus activation of TNF receptor 1 (TNFR1) and TNFR2, are clinically used to treat inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease and psoriasis. However, TNFR1 and TNFR2 work antithetically to balance immune resp...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Fabian Richter, Sarah K. Williams, Katharina John, Carina Huber, Camille Vaslin, Henri Zanker, Richard Fairless, Kira Pichi, Silke Marhenke, Arndt Vogel, Marie-Ann Dhaen, Stefanie Herrmann, Andreas Herrmann, Klaus Pfizenmaier, Heike Bantel, Ricarda Diem, Roland E. Kontermann, Roman Fischer
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2021-07-01
Edice:	Frontiers in Immunology
Témata:	TNF TNFR1 inflammatory diseases arthritis EAE multiple sclerosis
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fimmu.2021.705485/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!